RE:RE:not good
Independent market research showed that the market for MCNA is $400M in the US alone. There is basically no near term competition. If we assuming a modest market penetration of 60% of only the US and a conservative P/E ratio of 10x, and a profit margin of 25%, that gives a price of around $3.50 per share. Of course, this only happens if MCNA receives FDA approval but Telesta is working close with the FDA and chances are good that this will happen. The Seeking Alpha article goes into more detail: https://seekingalpha.com/instablog/13833412-sujan-lahiri/3273535-bioniche-a-home-run-buying-opportunity-in-biotech